A nested case-control study by Bezin et al. similarly reported a greater risk for all thyroid cancers, and for medullary thyroid cancers, among current GLP-1R agonist users compared with non-users with T2D (36). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.